Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2021 | 2020
Number of items: 3.

2021

Eichler, Martin ORCID: 0000-0001-9654-2207, Andreou, Dimosthenis, Golcher, Henriette, Hentschel, Leopold, Richter, Stephan, Hohenberger, Peter, Kasper, Bernd ORCID: 0000-0001-8425-8356, Pink, Daniel ORCID: 0000-0001-7243-7373, Jakob, Jens, Ashmawy, Hany, Hettmer, Simone, Tuchscherer, Armin, Grube, Matthias, Heidt, Vitali, Jentsch, Christina, Pablik, Jessica, Wardelmann, Eva, Kreitner, Karl-Friedrich, Kneser, Ulrich, Tonus, Carolin, Wimberger, Pauline, Schoffer, Olaf ORCID: 0000-0001-6922-7148, Reichardt, Peter, Wartenberg, Markus, Eberlein-Gonska, Maria, Bornhauser, Martin, Schmitt, Jochen ORCID: 0000-0003-0264-0960 and Schuler, Markus K. (2021). Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study. Oncol. Res. Treat., 44 (6). S. 301 - 310. BASEL: KARGER. ISSN 2296-5262

Eichler, Martin ORCID: 0000-0001-9654-2207, Pink, Daniel ORCID: 0000-0001-7243-7373, Menge, Franka, Jakob, Jens, Hentschel, Leopold, Richter, Stephan, Hohenberger, Peter, Kasper, Bernd, Andreou, Dimosthenis, Singer, Susanne, Gruetzmann, Robert, Dmytrow, Diana I., Arndt, Karin, Tuchscherer, Armin, Reichardt, Peter, Ahrens, Marit, Kunitz, Annegret, Mohm, Johannes, Bornhaeuser, Martin, Schmitt, Jochen and Schuler, Markus K. (2021). Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). Eur. J. Cancer Care, 30 (6). HOBOKEN: WILEY. ISSN 1365-2354

2020

Pink, Daniel, Richter, Adrian, Andreou, Dimosthenis, Richter, Stephan, Florcken, Anne, Deinzer, Christoph, Kasper, Bernd, Egerer, Gerlinde, Ivanyi, Philipp ORCID: 0000-0002-2862-7302, Tuchscherer, Armin, Kessler, Torsten, Schuler, Markus, Schmidt, Christian, Bahr, Jeannette, Ittermann, Till and Reichardt, Peter (2020). Which patients with pre-treated locally advanced or metastatic sarcoma benefit most from trabectedin treatment: First results of a retrospective study of the German Interdisciplinary Sarcoma Group (GISG-14-ReTraSarc). J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

This list was generated on Thu Nov 28 06:45:06 2024 CET.